Vertex Pharmaceuticals Inc

US

VRTX

Health Care

399.92 ₽

Current price

Buy
399.92 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    125 / 1361

  • Position in country

    2033 / 14179

  • Return on Assets, %

    17.7

    -40.3

  • Net income margin, %

    38.4

    -180

  • EBITDA margin, %

    39.6

    -168.2

  • Debt to Equity, %

    2.1

    3.2

  • Intangible assets and goodwill, %

    8.4

    0.2

  • Revenue CAGR 3Y, %

    16.7

    12.5

  • Total Equity change 1Y, %

    26.3

    -9

  • Revenue Y, % chg

    10.5

    0

  • P/E

    28.5

    31

  • P/BV

    5.8

    1.8

  • P/S

    10.3

    10.3

  • EV/S

    9.2

    7.5

  • EV/EBITDA

    22.8

    -1.6

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    15.1

    131.1

  • Forward P/E

    23

    21.4

  • Expected dividend per share

    0

    0

  • Payout Ratio, %

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Vertex Pharmaceuticals Inc

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Biomarin Pharmaceutical Inc

    00%

  • Seagen Inc

    00%

  • Amgen Inc

    00%

  • Moderna Inc

    00%

  • Alnylam Pharmaceuticals Inc

    00%

  • AbbVie Inc

    00%

  • Biogen Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    102492

  • Ticker

    VRTX.O

  • ISIN

    US92532F1003

  • IPO date

    1991-07-24

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-15

  • Date fact. publication of reports

    2023-12-31

Company Description

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: